Acetaminophen Patent Expiration
Acetaminophen was first introduced by Johnson And Johnson Consumer Inc Mcneil Consumer Healthcare Div
Acetaminophen Patents
Given below is the list of patents protecting Acetaminophen, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ofirmev |
US9399012 (Pediatric) | Reduced dose intravenous acetaminophen | Mar 11, 2032 | Mallinckrodt Hosp |
| Ofirmev | US9399012 | Reduced dose intravenous acetaminophen | Sep 11, 2031 | Mallinckrodt Hosp |
| Acetaminophen | US8741959 | Paracetamol for parenteral administration | Apr 19, 2030 | Fresenius Kabi Usa |
| Ofirmev |
US9610265 (Pediatric) | Reduced dose intravenous acetaminophen | May 13, 2029 | Mallinckrodt Hosp |
| Ofirmev |
US9987238 (Pediatric) | Reduced dose intravenous acetaminophen | May 13, 2029 | Mallinckrodt Hosp |
| Ofirmev | US10383834 | Reduced dose intravenous acetaminophen | Nov 13, 2028 | Mallinckrodt Hosp |
| Ofirmev | US9610265 | Reduced dose intravenous acetaminophen | Nov 13, 2028 | Mallinckrodt Hosp |
| Ofirmev | US9987238 | Reduced dose intravenous acetaminophen | Nov 13, 2028 | Mallinckrodt Hosp |
| Ofirmev |
US6992218 (Pediatric) | Method for obtaining aqueous formulations of oxidation-sensitive active principles |
Dec 06, 2021
(Expired) | Mallinckrodt Hosp |
| Ofirmev | US6992218 | Method for obtaining aqueous formulations of oxidation-sensitive active principles |
Jun 06, 2021
(Expired) | Mallinckrodt Hosp |
| Ofirmev |
US6028222 (Pediatric) | Stable liquid paracetamol compositions, and method for preparing same |
Feb 05, 2018
(Expired) | Mallinckrodt Hosp |
| Ofirmev | US6028222 | Stable liquid paracetamol compositions, and method for preparing same |
Aug 05, 2017
(Expired) | Mallinckrodt Hosp |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Acetaminophen's patents.
Latest Legal Activities on Acetaminophen's Patents
Given below is the list recent legal activities going on the following patents of Acetaminophen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Dec, 2021 | US8741959 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Nov, 2017 | US8741959 |
| Patent Issue Date Used in PTA Calculation Critical
| 03 Jun, 2014 | US8741959 |
| Recordation of Patent Grant Mailed Critical
| 03 Jun, 2014 | US8741959 |
| Email Notification Critical
| 16 May, 2014 | US8741959 |
| Issue Notification Mailed Critical
| 14 May, 2014 | US8741959 |
| Dispatch to FDC | 05 May, 2014 | US8741959 |
| Application Is Considered Ready for Issue Critical
| 05 May, 2014 | US8741959 |
| Issue Fee Payment Verified Critical
| 24 Apr, 2014 | US8741959 |
| Issue Fee Payment Received Critical
| 24 Apr, 2014 | US8741959 |
Acetaminophen's Family Patents
